Altimmune, Inc. (ALT)
3.235
-0.08
(-2.27%)
USD |
NASDAQ |
Mar 26, 13:33
Altimmune Cash from Investing (Quarterly) : -79.16M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -2.802B |
| CorMedix, Inc. | 3.297M |
| Amgen, Inc. | -693.00M |
| Viking Therapeutics, Inc. | 75.61M |
| Verastem, Inc. | -1.345M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.15M |
| Cash from Financing (Quarterly) | 80.83M |
| Free Cash Flow | -67.55M |
| Free Cash Flow Per Share (Quarterly) | -0.1903 |
| Free Cash Flow to Equity (Quarterly) | -38.93M |
| Free Cash Flow to Firm (Quarterly) | -18.28M |
| Free Cash Flow Yield | -24.06% |